Nordic Nanovector ASA announced the appointment of Pierre Dodion as Chief Medical Officer (CMO). Dr. Dodion is taking over the role from Dr. Christine Wilkinson Blanc, who is leaving the Company for personal reasons. Dr. Wilkinson Blanc will remain with the Company until January 2022 to ensure a smooth transition. Dr. Dodion joins Nordic Nanovector from Immunooncology Partners, a consultancy he founded to support biotech companies in clinical development, medical affairs and business development activities. In this role, he has acted as a consultant for Nordic Nanovector since April 2021, advising on Betalutin?'s clinical development. Dr Dodion has over 30 years' experience in the biopharmaceutical industry, spent mostly in the oncology and haematology areas. In this time, he has developed deep clinical development and medical affairs expertise, providing strategic insight and overseeing the coordination of multiple clinical trials. Furthermore, Dr. Dodion has supported the global launch of several products, including Sutent at Pfizer, Femara at Novartis and two further oncology products at Aventis. Dr Dodion is also serving as a specialist consultant in oncology for Alacrita, an international pharmaceutical and biotech consulting firm. Before that he served as Executive Vice President and CMO at Innate Pharmaceuticals, coordinating clinical development and medical affairs for several oncology programs. He has held executive clinical and/or corporate roles at Ariad Pharmaceuticals, Roche and UCB in addition to Pfizer, Novartis and Aventis.